Archive

Updates on Reducer and Tiara Programs will be presented at Advanced Cardiovascular Intervention 2020 Meeting

Posted on January 21, 2020
in
by Andrew Rose

  NASDAQ, TSX: NVCN Neovasc Provides Corporate Update   Vancouver, BC, January 21, 2020 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced...

Read More

Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

Posted on January 15, 2020
in
by Andrew Rose

  NASDAQ, TSX: NVCN   VANCOUVER, January 15, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt...

Read More

Neovasc Inc. Investor Update

Posted on January 13, 2020
in
by Andrew Rose

  NASDAQ, TSX: NVCN   VANCOUVER, January 13, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide...

Read More

Neovasc Reducer™ Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

Posted on December 11, 2019
in
by Andrew Rose

  - Educational events featuring the Reducer hosted in Germany and Italy -   VANCOUVER, CA, COBURG, DE, and COTIGNOLA, IT, November 22, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and...

Read More

Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

Posted on December 10, 2019
in
by Andrew Rose

 NASDAQ, TSX: NVCN   VANCOUVER, November 19, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that...

Read More